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Cangrelor use in patients undergoing percutaneous coronary intervention or 
neuro intervention with stent placement in a community hospital
R. Gopalani, Pharm.D., BCPS, J. Justiz, Pharm.D., S. Palma, Pharm.D., BCPS, 
A. Marr-Peralto, DNP, CCPC, ARNP-BC, AGACNP, M. Tadros, Pharm.D.
Baptist Hospital of Miami, Miami, FL
• Cangrelor (Kengreal) is a direct acting, reversible, IV P2Y12 receptor 
antagonist 
• It is approved by the FDA as an adjunct to percutaneous coronary 
intervention (PCI) to reduce the risk of periprocedural myocardial 
infarction (MI), repeat coronary vascularization, and stent 
thrombosis in patients who have not received an oral P2Y12
inhibitor or glycoprotein IIb/IIIa inhibition
• The novel advantage of  cangrelor includes its rapid onset (within 
2 min) and offset of action (1 hr post end of infusion)
• The CHAMPION-PHOENIX trial demonstrated that cangrelor was 
associated with a lower risk of recurrent MI or stent thrombosis at 
the cost of an increase in minor bleeding with no difference in 
major bleeding compared to clopidogrel
• Due to its limited niche, marginal clinical outcomes benefit, 
significant cost burden and refuted place in therapy, cangrelor is a 
non-formulary (NF) medication at Baptist Hospital (BH); its  
medical necessity is evaluated on a case-by-case basis in PCI 
patients
• Due to its quick onset and offset, cangrelor has also been studied 
in an off-label fashion for use during neurovascular interventions 
and as a bridge to cardiac surgery
All authors of this presentation have nothing to disclose.
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To evaluate the appropriateness of cangrelor use and determine if 
patient selection was optimal as a non-formulary agent in a 
community hospital
• Single center retrospective observational study
• Evaluation period: January 1st, 2018 to January 31st, 2019 
• Inclusion criteria: Patients receiving at least one dose of cangrelor 
during evaluation period 
• Primary outcomes: 
• Compliance with the FDA labeled use 
• Appropriate transition to an oral P2Y12 agent
• Secondary outcomes:
• Compliance with BH criteria for NF usage 
• Adverse drug events  
• Mortality rate 
• Length of stay (LOS)
• 30-day readmission rate due to cardiovascular or 
neurological event
• Descriptive statistics used in analysis 
• Small sample size
• Due to incomplete documentation of dose and duration, unable 
to assess accurate bolus, infusion and duration in all patients
• Limited published literature to assess for appropriate dose, 
duration , safety and efficacy in patients with neurovascular 
intervention
• Of the total cangrelor use during the review period, 64% (18/28) 
patients received it for a PCI and 36% (10/28) received it during a 
neuro intervention
• 78% of PCI patients met FDA labeled indication for cangrelor, 
primary reason for non-compliance included oral  P2Y12 loading 
dose preceding cangrelor administration in 4/18 (22%) patients
• In neuro intervention patients ticagrelor load was administered 
concurrent to cangrelor infusion
• Cangrelor use was justified in 72% of coronary patients per BH 
criteria for NF usage
• All eligible patients were transitioned to an oral agent prior to 
completion of cangrelor infusion
• Cangrelor administration was documented in all patients; 
however, specific bolus or infusion doses and duration of infusion 
was not documented accurately and/or consistently 
• Opportunities to improve cangrelor use at BH were identified 
including:
o Procedural room staff education to enhance documentation of 
drug, dose and duration on patient profile 
o Need to revisit formulary status and establish drug  specific 




• PCI w/ stent = 18/28
• Cerebral angiography w/ stenting = 9/28
• Cerebral angiography w/ mechanical 
thrombectomy/ angioplasty = 1/28
Mean age,  years (range) 63 (36-88)
Gender – male, n (%) 16/28  (57)
Admitting diagnosis
• STEMI = 13
• NSTEMI = 3
• V Fib arrest/ Cardiogenic shock=2
• Intracranial aneurysm = 5
• Ischemic stroke = 5 
Primary Outcomes, n (%)
PCI (n=18) Neuro (n=10)
Compliance with 




Transition to oral P2Y12 agent 17/17 (100)* 10/10 (100%)
Secondary Outcomes
PCI  (n=18) Neuro (n=10)
Compliance with NF criteria 13/18 (72) N/A







Mortality rate, n (%) 2/18 (11.1)** 2/10 (20)**
Median LOS, days (range) 3.9 (0.1-33) 9.25 (2.5-18.3)
30-day Readmission rate, n (%) 2/16(12.5) 1/8 (12.5)**
* 1 patient expired prior to completion of procedure
^ claudication
^^ Evolving stroke or hypercoagulable state
^^^ access site bleeding or hematoma
** not related to cangrelor use
